Lung cancer: open trials in New Zealand

• NCT06881784

  Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  Trial Treatment · Phase 3 · Revolution Medicines, Inc.

  Auckland City Hospital - Cancer and Blood Research, Grafton

  Registry updated 2026-11-06

• NCT06793215

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  Trial Treatment · Phase 3 · Hoffmann-La Roche

  Harbour Cancer and Wellness, Auckland · Wellington Hospital, Newtown

  Registry updated 2026-11-05

• NCT04613596

  Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  Trial Treatment · Phase 2/3 · Mirati Therapeutics Inc.

  Health New Zealand - Te Whatu Ora - MidCentral, Palmerston North

  Registry updated 2026-10-30

• NCT06623422

  A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC

  Dunedin Hospital (Site 2202), Dunedin · Waikato Hospital (Site 2204), Hamilton · Tauranga Hospital-Bay of Plenty Clinical Trials Unit (Site 2201), Tauranga

  Registry updated 2026-10-30

• NCT07472517

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  Trial Treatment · Phase 3 · Boehringer Ingelheim

  Auckland City Hospital, Auckland · Waikato Hospital, Hamilton

  Registry updated 2026-10-28

• NCT06345729

  A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC

  Auckland City Hospital (Site 3400), Auckland

  Registry updated 2026-10-26

• NCT06561386

  A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  Trial Treatment · Phase 3 · Bristol-Myers Squibb

  Auckland City Hospital, Auckland · Dunedin · Tauranga · Tauranga · Wellington

  Registry updated 2026-10-23

• NCT06312137

  A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

  Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC

  Auckland City Hospital (Site 0800), Auckland

  Registry updated 2026-10-15

• NCT07671092

  Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC

  Trial Treatment · Early phase 1 · RayzeBio, Inc.

  Christchurch

  Registry updated 2026-10-13

• NCT05176483

  Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  Trial Treatment · Phase 1 · Exelixis

  Grafton · Hamilton

  Registry updated 2026-10-01

• NCT06427941

  A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

  Trial Treatment · Phase 1/2 · BeOne Medicines

  Auckland City Hospital, Auckland

  Registry updated 2026-09-16

• NCT05235165

  Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

  Trial Treatment · Phase 3 · Children's Oncology Group

  Christchurch Hospital, Christchurch · Starship Children's Hospital, Grafton

  Registry updated 2026-08-25

All Lung cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error